Article

Medtronic: For your approval

This is a sample of how your ads will appear around selected BPHcontent. Your ads will be the exclusive content on BPH articles andwill rotate with the other sponsors on General News items.

This is a sample of how your ads will appear around selected BPHcontent. Your ads will be the exclusive content on BPH articles andwill rotate with the other sponsors on General News items.

If you can, please provide up to 150 words to include about your company.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
1 expert is featured in this series.
Targeted Therapy in mHSPC: Effects of Mutation Absence
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
1 expert is featured in this series.
Treatment Strategies for Symptomatic Bone Metastases in mHSPC
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, answers a question during a Zoom video interview
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Related Content
FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
May 29th 2025

FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer

Hannah Clarke
The company plans to submit a Biologics License Application to the FDA at the end of 2026.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Subcutaneous nivolumab approved in EU, Canada for solid tumors
May 28th 2025

Subcutaneous nivolumab approved in EU, Canada for solid tumors

Hannah Clarke
The approvals are supported by findings from the phase 3 CheckMate-67T trial.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test
May 27th 2025

Application submitted to FDA for 510(k) clearance of Men’s Sexual Health Test

Hannah Clarke
The single-use test can deliver diagnostic results for chlamydia and gonorrhea in approximately 30 minutes.
Combination therapy linked to longer OS vs ADT in veterans with mHSPC
May 27th 2025

Combination therapy linked to longer OS vs ADT in veterans with mHSPC

Hannah Clarke
However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.
© 2025 MJH Life Sciences

All rights reserved.